Related Experiment Video

Updated: Aug 14, 2026

Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease
12:47

Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease

Published on: February 3, 2012

Prevalence of arylsulfatase A pseudodeficiency allele in metachromatic leukodystrophy patients from Poland

A Lugowska1, B Czartoryska, A Tylki-Szymańska

  • 1Department of Genetics, Institute of Psychiatry and Neurology, Children's Memorial Health Institute, Warsaw, Poland. lugowska@ipin.edu.pl

European Neurology
|August 31, 2000
PubMed

Insights

The Arylsulfatase A (ASA) pseudodeficiency (PD) allele was found in 9% of Polish metachromatic leukodystrophy (MLD) patients, suggesting a potential link between MLD and PD mutations. Further research is needed to understand this genetic interaction.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Metachromatic leukodystrophy (MLD) is a rare genetic disorder affecting the nervous system.
  • Arylsulfatase A (ASA) deficiency is the underlying cause of MLD.
  • Pseudodeficiency (PD) alleles of ASA are common in some populations but do not typically cause MLD.

Purpose of the Study:

  • To investigate the prevalence of the ASA pseudodeficiency (PD) allele in Polish patients with metachromatic leukodystrophy (MLD).
  • To explore the potential genetic interaction between MLD-causing mutations and the ASA PD allele.

Main Methods:

  • Genotyping was performed on 22 MLD patients from Poland.
  • The presence of the ASA PD allele was assessed in patients and compared to healthy controls.
  • One patient with a unique mutation affecting N-glycosylation was analyzed.

Main Results:

  • The ASA PD allele was detected in a heterozygous state in 4 out of 22 MLD patients (9% prevalence).
  • The estimated frequency of the PD allele in healthy controls was 6-7%.
  • One MLD patient carried an additional mutation causing loss of an N-glycosylation site.

Conclusions:

  • The study suggests a potentially higher prevalence of the ASA PD allele in MLD patients compared to the general population.
  • The findings raise questions about the interplay between MLD mutations and the occurrence of PD alleles.
  • Further investigation is warranted to elucidate the genetic mechanisms underlying this association.

More Related Videos

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...